Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Trial Profile

Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs PF 4136309 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2016 Results published in the Lancet Oncology
    • 22 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top